285 related articles for article (PubMed ID: 16193937)
1. [The risk of malignancy after organ transplantation].
Gürlich R; Novotný J; Stríz I; Honsová E; Oliverius M; Janousek L; Pokorná E; Maruna P
Cas Lek Cesk; 2005; 144(9):597-600; discussion 600-1. PubMed ID: 16193937
[TBL] [Abstract][Full Text] [Related]
2. [Cancer in organ transplanted patients].
Pfeffer PF
Tidsskr Nor Laegeforen; 1999 Oct; 119(25):3792-4. PubMed ID: 10574060
[TBL] [Abstract][Full Text] [Related]
3. Infectious risk in pediatric organ transplant recipients: is it increased with the new immunosuppressive agents?
Renoult E; Buteau C; Lamarre V; Turgeon N; Tapiero B
Pediatr Transplant; 2005 Aug; 9(4):470-9. PubMed ID: 16048599
[TBL] [Abstract][Full Text] [Related]
4. Gynecological issues after organ transplantation.
Kaminski P; Bobrowska K; Pietrzak B; Bablok L; Wielgos M
Neuro Endocrinol Lett; 2008 Dec; 29(6):852-6. PubMed ID: 19112398
[TBL] [Abstract][Full Text] [Related]
5. For organ transplant recipients, cancer threatens long-term survival.
Ross K
J Natl Cancer Inst; 2007 Mar; 99(6):421-2. PubMed ID: 17374827
[No Abstract] [Full Text] [Related]
6. [Post-transplantation malignant tumors and the challenges of immunosuppressive therapy in transplanted patients developing lymphoma. Mycophenolic acid as a possibility].
Végso G
Magy Onkol; 2009 Jun; 53(2):149-56. PubMed ID: 19581181
[TBL] [Abstract][Full Text] [Related]
7. [Cancer following organ transplantation].
Birkeland SA; Eklund B; Jakobsen A
Nord Med; 1994; 109(6-7):197-201. PubMed ID: 8015916
[TBL] [Abstract][Full Text] [Related]
8. Malignancies in pediatric solid organ transplant recipients: epidemiology, risk factors, and prophylactic approaches.
Paramesh A; Cannon R; Buell JF
Curr Opin Organ Transplant; 2010 Oct; 15(5):621-7. PubMed ID: 20733488
[TBL] [Abstract][Full Text] [Related]
9. Solid organ transplant: medication management issues.
Trofe J; Wimberley S
J Am Pharm Assoc (Wash); 2000; 40(5 Suppl 1):S48-9. PubMed ID: 11029867
[TBL] [Abstract][Full Text] [Related]
10. Infectious complications of immunosuppressive medications in organ transplant recipients.
Green M; Michaels MG
Pediatr Infect Dis J; 2007 May; 26(5):443-4. PubMed ID: 17468657
[No Abstract] [Full Text] [Related]
11. Renal disease in recipients of nonrenal solid organ transplantation.
Ojo AO
Semin Nephrol; 2007 Jul; 27(4):498-507. PubMed ID: 17616280
[TBL] [Abstract][Full Text] [Related]
12. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology.
Aguado JM; Torre-Cisneros J; Fortún J; Benito N; Meije Y; Doblas A; Muñoz P
Clin Infect Dis; 2009 May; 48(9):1276-84. PubMed ID: 19320593
[TBL] [Abstract][Full Text] [Related]
13. Predictors of cancer risk in the long-term solid-organ transplant recipient.
Sherston SN; Carroll RP; Harden PN; Wood KJ
Transplantation; 2014 Mar; 97(6):605-11. PubMed ID: 24202142
[TBL] [Abstract][Full Text] [Related]
14. Depressed immunity and the development of cancer.
Penn I
Cancer Detect Prev; 1994; 18(4):241-52. PubMed ID: 7982234
[TBL] [Abstract][Full Text] [Related]
15. How can we improve the long-term outcome after pediatric organ transplantation?
Debray D
Curr Opin Organ Transplant; 2010 Oct; 15(5):588-9. PubMed ID: 20689434
[No Abstract] [Full Text] [Related]
16. Immunosuppressive therapy and post-transplant malignancy.
Domhan S; Zeier M; Abdollahi A
Nephrol Dial Transplant; 2009 Apr; 24(4):1097-103. PubMed ID: 18978068
[No Abstract] [Full Text] [Related]
17. Incidence of cancer after immunosuppressive treatment for heart transplantation.
Ippoliti G; Rinaldi M; Pellegrini C; Viganò M
Crit Rev Oncol Hematol; 2005 Oct; 56(1):101-13. PubMed ID: 15979322
[TBL] [Abstract][Full Text] [Related]
18. Nutritional and metabolic issues in solid organ transplantation: targets for future research.
Ward HJ
J Ren Nutr; 2009 Jan; 19(1):111-22. PubMed ID: 19121784
[TBL] [Abstract][Full Text] [Related]
19. Nonimmune complications after transplantation.
Choquette M; Goebel JW; Campbell KM
Pediatr Clin North Am; 2010 Apr; 57(2):505-21, table of contents. PubMed ID: 20371049
[TBL] [Abstract][Full Text] [Related]
20. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
